JOINN adheres to the mission of "Safety Assessment and Life Cycle Monitoring for Your Pharmaceutical Innovations"
Consideration of Implementation for Postmarketing Carcinogenicity Studies Based on a Retrospective Analysis of Approved New Drugs by US FDA in the Past Ten Years
2026.07.28
Summary of Three Toxicity Study of Repeated Intravenous Infusion of Exatecan Derivative-ADCs to Cynomolgus Monkey
